These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and drawbacks of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the thoracic esophagus. Wolfárd A; Paszt A; Szentpáli K; Hideghéthy K; Uhercsák G; Németh I; Tiszlavicz L; Lázár G Hepatogastroenterology; 2011; 58(109):1214-9. PubMed ID: 21937381 [TBL] [Abstract][Full Text] [Related]
25. Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma. Kuroda J; Yoshida M; Kitajima M; Yanagisawa A; Matsubara T; Yamaguchi T; Osamura Y; Ohta K; Kubota K; Beck Y; Yamashita Y J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():88-94. PubMed ID: 22486878 [TBL] [Abstract][Full Text] [Related]
26. Chemoradiotherapy in esophageal cancer: toxicity is in the eye of the beholder. Ilson DH J Thorac Oncol; 2009 Mar; 4(3):277-8. PubMed ID: 19247080 [No Abstract] [Full Text] [Related]
27. Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus. Stahl M; Lehmann N; Walz MK; Stuschke M; Wilke H Eur J Cancer; 2012 Nov; 48(16):2977-82. PubMed ID: 22503151 [TBL] [Abstract][Full Text] [Related]
28. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Fogh SE; Yu A; Kubicek GJ; Scott W; Mitchell E; Rosato EL; Berger AC Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1372-6. PubMed ID: 21106309 [TBL] [Abstract][Full Text] [Related]
29. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M Dis Esophagus; 2015; 28(4):358-64. PubMed ID: 24612033 [TBL] [Abstract][Full Text] [Related]
30. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465 [TBL] [Abstract][Full Text] [Related]
31. Disparities in survival after trimodality therapy for esophageal adenocarcinoma. Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155 [TBL] [Abstract][Full Text] [Related]
32. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Merkow RP; Bilimoria KY; McCarter MD; Chow WB; Ko CY; Bentrem DJ Ann Surg Oncol; 2012 Feb; 19(2):357-64. PubMed ID: 21769460 [TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. Hyngstrom JR; Posner MC J Surg Oncol; 2010 Mar; 101(4):299-304. PubMed ID: 20187065 [TBL] [Abstract][Full Text] [Related]
34. Effect of neoadjuvant chemoradiotherapy on perioperative immune function of patients with locally advanced esophageal cancer. Tan JT; Yang Y; Mao NQ; Liu DS; Huang DM; Pan H; Xie T; Pan Q; Yang L; Zhong JH; Zuo CT Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27766708 [TBL] [Abstract][Full Text] [Related]
35. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus? Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971 [TBL] [Abstract][Full Text] [Related]
36. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Scheer RV; Fakiris AJ; Johnstone PA Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):996-1001. PubMed ID: 20584580 [TBL] [Abstract][Full Text] [Related]
37. Influence of the Extent and Dose of Radiation on Complications After Neoadjuvant Chemoradiation and Subsequent Esophagectomy With Gastric Tube Reconstruction With a Cervical Anastomosis. Koëter M; Kathiravetpillai N; Gooszen JA; van Berge Henegouwen MI; Gisbertz SS; van der Sangen MJ; Luyer MD; Nieuwenhuijzen GA; Hulshof MC Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):813-821. PubMed ID: 28244418 [TBL] [Abstract][Full Text] [Related]
38. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Nakamura T; Hayashi K; Ota M; Eguchi R; Ide H; Takasaki K; Mitsuhashi N Am J Surg; 2004 Sep; 188(3):261-6. PubMed ID: 15450831 [TBL] [Abstract][Full Text] [Related]
39. Re: Is an involved circumferential resection margin following oesphagectomy for cancer an important prognostic indicator? Griffiths EA; Pritchard SA Interact Cardiovasc Thorac Surg; 2010 Nov; 11(5):648. PubMed ID: 20962166 [No Abstract] [Full Text] [Related]
40. Is the predictive ability of positron emission tomography after neoadjuvant treatment for esophageal cancer ready for prime-time? Groth SS; D'Cunha J Semin Thorac Cardiovasc Surg; 2011; 23(2):87-8. PubMed ID: 22041033 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]